Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors

Hormones and Cancer

Volumn 1, Issue 1, 2010, Pages 44-54

  Liao, Chun Peng ^a   Liang, Mengmeng ^a   Roy Burman, Pradip ^a   Jeong, Joseph H ^b   Cohen, Michael B ^c   Flesken Nikitin, Andrea ^d   Nikitin, Alexander Y ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d Department of Obstetrics Gynecology   (United States)

Author keywords

Androgen dependent and androgen depletion independent prostate cancer; Conditional pten deletion mouse model of prostate adenocarcinoma; Mouse prostate cancer cell lines; Prostate sarcomatoid carcinoma

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CELL MARKER; CYTOKERATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VIMENTIN;

ALLELE; ANDROGEN DEPRIVATION THERAPY; ANDROGEN METABOLISM; ANDROGEN THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RECURRENCE; CARCINOGENICITY; CASTRATION; CELL STRUCTURE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBROBLAST; GENE DELETION; GENE LOCUS; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION;

ANIMALS; BLOTTING, WESTERN; CASTRATION; CELL LINE, TUMOR; FEMALE; MALE; MICE; MICE, KNOCKOUT; MICE, SCID; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78650193523     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-009-0005-y     Document Type: Article

References (34)

1. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276-308
2. Bonkhoff H, Berges R (2009) From pathogenesis to prevention of castration resistant prostate cancer. Prostate 70:100-112
3. Roy-Burman P, Tindall DJ, Robins DM et al (2005) Androgens and prostate cancer: are the descriptors valid? Cancer Biol Ther 4:4-5
4. Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10:18-25
5. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555
6. Waltering KK, Helenius MA, Sahu B et al (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69:8141-8149
7. Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10:981-991
8. Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB (2004) Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 11:225-254
9. Abate-Shen C, Brown PH, Colburn NH et al (2008) The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res (Phila Pa) 1:161-166
10. Trotman LC, Niki M, Dotan ZA et al (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1:385-396
11. Ma X, Ziel-van der Made AC, Autar B et al (2005) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65:5730-5739
12. Zhou Z, Flesken-Nikitin A, Corney DC et al (2006) Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66:7889-7898
13. Bruxvoort KJ, Charbonneau HM, Giambernardi TA et al (2007) Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 67:2490-2496
14. Wang S, Gao J, Lei Q et al (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221
15. Liao CP, Zhong C, Saribekyan G et al (2007) Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67:7525-7533
16. van Bokhoven A, Varella-Garcia M, Korch C et al (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205-225
17. Navone NM, Olive M, Ozen M et al (1997) Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3:2493-2500
18. Chen ME, Lin SH, Chung LW, Sikes RA (1998) Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 273:17618-17625
19. Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y (2009) Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Prostate (in press)
20. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57:3325-3330
21. Jiao J, Wang S, Qiao R et al (2007) Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 67:6083-6091
22. Choi J, Burns AA, Williams RM et al (2007) Core-shell silica nanoparticles as fluorescent labels for nanomedicine. J Biomed Opt 12:1-12
23. Wu X, Wu J, Huang J et al (2001) Generation of a prostate epithelial cell specific Cre transgenic mouse model for tissue specific gene ablation. Mech Dev 101:61-69
24. Leong KG, Wang BE, Johnson L, Gao WQ (2008) Generation of a prostate from a single adult stem cell. Nature 456:804-808
25. Nagy A, Gertsenstein M, Vintersten K, Behringer R (2003) Manipulating the mouse embryo. A laboratory manual, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, p 389
26. Leiblich A, Cross SS, Catto JW, Pesce G, Hamdy FC, Rehman I (2007) Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate 67:1761-1769
27. Zhou Z, Flesken-Nikitin A, Nikitin AY (2007) Prostate cancer associated with p53 and Rb deficiency arises from the stem/ progenitor cell-enriched proximal region of prostatic ducts. Cancer Res 67:5683-5690
28. Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S (2007) Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 67:5789-5797
29. Tran CP, Lin C, Yamashiro J, Reiter RE (2002) Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 1:113-121
30. Hansel DE, Herawi M, Montgomery E, Epstein JI (2007) Spindle cell lesions of the adult prostate. Mod Pathol 20:148-158
31. Shappell SB, Thomas GV, Roberts RL et al (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64:2270-2305
32. Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
33. Yuan X, Li T, Wang H et al (2006) Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 169:682-696
34. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y (2009) Wnt/betacatenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 20:765-776